SC
RMD icon

Stephens Consulting’s ResMed RMD Stock Holding History

Stephens Consulting’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5
Closed -$1.29K – 997
2025
Q2 		$1.29K Buy
+5
New +$1.19K ﹤0.01% 597
2022
Q2 		– Sell
-50
Closed -$12.1K – 565
2022
Q1 		$12.1K Sell
50
-50
-50% -$12.1K 0.01% 332
2021
Q4 		$26K Buy
+100
New +$25.9K 0.02% 270

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Stephens Consulting's RMD Position: Q3 2025 in Review

Stephens Consulting sold out of ResMed (RMD) in Q3 2025, closing a stake of 5 shares — an estimated $1.29K sold.

Stephens Consulting first reported a position in RMD in Q4 2021 and held it in 3 quarters. The position peaked at $26K in Q4 2021. 950 funds tracked by Wall St. Rank hold RMD as of Q3 2025.

  • Stephens Consulting reported no remaining ResMed position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 5 ResMed shares in Q3 2025, an estimated $1.29K.
  • Stephens Consulting first reported a position in ResMed in Q4 2021 and held it in 3 quarters.
  • Stephens Consulting's ResMed position peaked at $26K in Q4 2021.
  • 950 funds tracked by Wall St. Rank held ResMed as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.